Clinical trials: Non Metastatic Pancreatic Cancer
Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
This phase I trial studies the side effects and best dose of talazoparib in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or…
- Conditions
- Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma, HER2/Neu Negative, Hormone-Resistant Prostate Cancer
- Trial name
- NCT02567396
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib
- Sponsor
- National Cancer Institute (NCI)
PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or…
- Conditions
- PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation
- Trial name
- NCT06922591
- Testing
- TNG462, RMC-9805, RMC-6236
- Where
- 18 sites in United States
- Volunteers
- 183 people
- Sponsor
- Tango Therapeutics, Inc.
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors.
- Trial name
- NCT07488676
- Testing
- ASP546C
- Where
- 21 sites in United States, Japan
- Volunteers
- 150 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Pancreatic Cancer Non-resectable
Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer
This phase-2 monocenter non-randomized prospective clinical trial evaluates the effectiveness of minimally invasive microwave ablation plus immunotherapy for unresectable non-metastatic locally advanced pancreatic cancer.
- Trial name
- MIMIPAC (NCT04156087)
- Testing
- Durvalumab 50 MG/ML, Tremelimumab, Gemcitabine
- Where
- Belgium
- Volunteers
- 12 people
- Sponsor
- Baki Topal
Solid Tumors, Neoplasms (Cancer / Tumors)
Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor
The goal of this clinical trial is to learn if Trastuzumab Rezetecan can treat advanced solid tumors with HER-2 expression in adult participants.
- Conditions
- Solid Tumors, Neoplasms (Cancer / Tumors), Advanced Malignant Solid Neoplasm, Locally Advanced Malignant Solid Neoplasm
- Trial name
- NCT07631884
- Testing
- Trastuzumab Rezetecan
- Volunteers
- 15 people
- Sponsor
- Haihua Yuan
Breast Cancer, Ovarian Cancer
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.
- Conditions
- Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT05239143
- Testing
- P-MUC1C-ALLO1 CAR-T cells, Rimiducid
- Where
- 14 sites in United States
- Volunteers
- 180 people
- Sponsor
- Poseida Therapeutics, Inc.
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are…
- Conditions
- Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Pancreas Adenocarcinoma, Biliary Tract Cancer
- Trial name
- NCT06451497
- Testing
- ZM008
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Zumutor Biologics Inc.
Pancreatic Neuroendocrine Tumors
The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors
This study is a multi-center, prospective, non-interventional (NI) study evaluating the safety and efficacy of sunitinib in Chinese patients with progressive, unresectable, advanced or metastatic well-differentiated, pancreatic…
- Trial name
- NCT02282059
- Testing
- sunitinib
- Where
- 24 sites in China
- Volunteers
- 100 people
- Sponsor
- Pfizer
Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).
- Conditions
- Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma
- Trial name
- NCT04068896
- Testing
- NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane
- Where
- 20 sites in United States
- Volunteers
- 89 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Solid Tumor, Adult, Solid Tumor
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
The goal of this study is to test A2B530,an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), and other…
- Conditions
- Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms
- Trial name
- EVEREST-1 (NCT05736731)
- Testing
- A2B530, xT-Onco with HLA-LOH Assay
- Where
- 8 sites in United States
- Volunteers
- 160 people
- Sponsor
- A2 Biotherapeutics Inc.
Pancreatic Cancer, Hepatocellular Cancer
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
This study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors.
- Conditions
- Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer
- Trial name
- NCT05070247
- Testing
- TAK-500, Pembrolizumab, Tocilizumab
- Where
- 12 sites in United States
- Volunteers
- 61 people
- Sponsor
- Takeda
Solid Tumor, Adult, Pancreatic Cancer
Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors
Basket trial concept to independently and simultaneously assess the effects of the association of atezolizumab + BDB001 + radiotherapy in multiple solid tumors.
- Conditions
- Solid Tumor, Adult, Pancreatic Cancer, Virus-associated Tumors, Non Small Cell Lung Cancer
- Trial name
- AGADIR (NCT03915678)
- Testing
- Association atezolizumab + BDB001 + RT, Association atezolizumab + BDB001+ RT
- Where
- 11 sites in France
- Volunteers
- 247 people
- Sponsor
- Institut Bergonié
Solid Tumors
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
DS-6051b is an orally administered inhibitor of the tyrosine kinases (ROS1) and neurotropic tyrosine kinase receptors (NTRK). This phase 1 first-in-human study evaluates safety and tolerability of DS-6051b in cancer subjects and…
- Trial name
- NCT02279433
- Testing
- DS6051b
- Where
- 6 sites in United States
- Volunteers
- 46 people
- Sponsor
- Nuvation Bio Inc.
Pancreatic Cancer
Vorinostat Plus Radiation Therapy in Pancreatic Cancer
Primary Endpoint: To determine the maximum tolerated dose (MTD) of vorinostat + radiation therapy (RT) in patients with locally advanced pancreatic cancer (LAPC). Secondary Endpoints: 1.
- Trial name
- NCT00831493
- Testing
- Chemoradiation (Radiation Therapy), Vorinostat
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer
Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer
This study aims to further observe and evaluate whether the three-week administration of albumin-bound paclitaxel combined with gemcitabine is equivalent to the four-week administration in the treatment of inoperable locally…
- Trial name
- NCT05035147
- Testing
- albumin-bound paclitaxel
- Where
- China
- Volunteers
- 934 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Pancreas Cancer, Localized Pancreas Cancer
Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancrease Cancer
A prospective evaluation of neoadjuvant FOLFIRINOX regimen in patients with non-metastatic pancreas cancer (Baylor University Medical Center and Texas Oncology Experience)
- Conditions
- Pancreas Cancer, Localized Pancreas Cancer, Non-metastatic Pancreas Cancer
- Trial name
- NCT01771146
- Testing
- FOLFIRINOX Regimen
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Baylor Research Institute
Pancreatic Cancer, Pancreatic Cancer Non-resectable
RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer
This is a Phase I, multi center study to evaluate the safety and efficacy and determine the maximum tolerated dose (MTD) of RP72 as monotherapy and RP72 in combination with Gemcitabine in patients with pancreatic cancer.
- Conditions
- Pancreatic Cancer, Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic
- Trial name
- NCT04338763
- Testing
- RP72, Gemcitabine
- Where
- 2 sites in Taiwan
- Volunteers
- 48 people
- Sponsor
- Rise Biopharmaceuticals, Inc.
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
- Trial name
- NCT05379985
- Testing
- RMC-6236
- Where
- 21 sites in United States
- Volunteers
- 754 people
- Sponsor
- Revolution Medicines, Inc.
Breast Cancer, Pancreatic Cancer
Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC
This study is a Phase I, first in human, dose-escalation study of MORAb-066, an investigational humanized immunoglobulin G (IgG) monoclonal antibody (mAb) that targets TF-expressing malignancies that include breast, pancreatic…
- Conditions
- Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT01761240
- Testing
- MORAb-066
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Morphotek
Advanced Cancer, Metastatic Cancer
Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
This study will evaluate safety, tolerability, drug levels, molecular effects and clinical activity of MRTX849 (adagrasib) in combination with BI 1701963 in patients with advanced solid tumors that have a KRAS G12C mutation.
- Conditions
- Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Colon, Malignant Neoplasm of Lung
- Trial name
- NCT04975256
- Testing
- MRTX849, BI 1701963
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Mirati Therapeutics Inc.